Stephen Wiviott, MD: Changes in the Treatment of Type 2 Diabetes


Stephen Wiviott, MD, principal investigator of the DECLARE-TIMI 58 trial of dapagliflozin, discusses more data to be published from the study, as well as the changes that SGLT2 inhibitors are contributing to the treatment of diabetes.

Video credits to MD Magazine YouTube channel





  • Your reaction?
    Angry Angry
    0
    Angry
    Lol Lol
    0
    Lol
    Love It! Love It!
    0
    Love It!
    Nice Nice
    0
    Nice
    Now I Know Now I Know
    0
    Now I Know
    Sad Sad
    0
    Sad
    Surprised Surprised
    0
    Surprised
    Wow! Wow!
    0
    Wow!
    WTF WTF
    0
    WTF

    Stephen Wiviott, MD: Changes in the Treatment of Type 2 Diabetes

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    log in

    reset password

    Back to
    log in